Sign In
Buy MEDP
$450.82
+5.23 (+1.17%)
At Close: Jun 03, 2026
Why Medpace Stock Soared Today
06:17pm, Tuesday, 25'th Oct 2022
The clinical trial specialist is winning new business at an impressive clip.
Medpace Holdings, Inc. (MEDP) Q3 2022 Earnings Call Transcript
04:14pm, Tuesday, 25'th Oct 2022
Medpace Holdings, Inc. (NASDAQ:MEDP ) Q3 2022 Results Conference Call October 25, 2022 9:00 AM ET Company Participants Lauren Morris - IR August Troendle - CEO Jesse Geiger - President Kevin Brady - C
Medpace Earnings Are 'Almost Unbelievable'; MEDP Stock Flies
12:58pm, Tuesday, 25'th Oct 2022
Medpace earnings soared in Q3 as weakness in contract awards turned to strength, sending MEDP stock surging. The post Medpace Earnings Are 'Almost Unbelievable'; MEDP Stock Flies appeared first on Inv
Medpace (MEDP) Beats Q3 Earnings and Revenue Estimates
06:48pm, Monday, 24'th Oct 2022
Medpace (MEDP) delivered earnings and revenue surprises of 39.46% and 8.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Horror Movies Are Scary Profitable
11:54am, Saturday, 15'th Oct 2022
Plus a look at what's happening in the markets and a couple of stocks worth watching.
Medpace Holdings, Inc. to Report Third Quarter 2022 Financial Results on October 24, 2022
04:05pm, Tuesday, 27'th Sep 2022
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2022 financial results after the market close on Monday, Octobe
There are three reasons health care is the market's best sector today. These eight stocks are the most worry-free.
02:22pm, Saturday, 06'th Aug 2022 MarketWatch
Health-care stocks have both growth and defensive characteristics.
Tandem Diabetes (TNDM) Q2 Earnings Miss, Sales View Cut
12:40pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Factoring the pandemic and competitive pressure as well as the evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) cuts its full-year guidance.
3 Reasons Growth Investors Will Love Medpace (MEDP)
04:45pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
CVS Health (CVS) Q2 Earnings Beat Estimates, Margins Down
04:30pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
CVS Health (CVS) posts better-than-expected results in Q2, with robust performances across all operating segments driving the top line.
Exact Sciences (EXAS) Q2 Earnings Top Estimates, Margins Down
04:17pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Exact Sciences (EXAS) posts better-than-expected earnings and revenues in Q2 with robust performances across the Screening and Precision Oncology segments.
Charles River (CRL) Q2 Earnings Top Estimates, 2022 View Cut
02:27pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Revenue decline in the CDMO business drag Charles River's (CRL) Manufacturing Solutions revenues down.
3 Reasons Growth Investors Will Love Medpace (MEDP)
02:17pm, Wednesday, 03'rd Aug 2022
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
STERIS (STE) Q1 Earnings Match Estimates, EPS View Down
01:54pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
STERIS' (STE) revenues at AST improve driven by increased demand from medical device and biopharma customers.
Henry Schein (HSIC) Q2 Earnings Top Estimates, '22 EPS View Up
04:14pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Henry Schein (HSIC) reports better-than-expected Q2 earnings with impressive sales growth across the Medical and Technology and Value-added Services segments.
